High purity Montelukast sodium powder cas no. 151767-02-1 CAS NO.151767-02-1
- FOB Price: USD: 20.00-30.00 /Kilogram Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,
- Available Specifications:
99%(1-9)Kilogram99%(10-50)Kilogram
- Product Details
Keywords
- 151767-02-1
- Montelukast sodium
- Suitable for reducing symptoms caused by allergic rhinitis
Quick Details
- ProName: High purity Montelukast sodium powder ...
- CasNo: 151767-02-1
- Molecular Formula: C35H35ClNNaO3S
- Appearance: White Powder
- Application: Suitable for reducing symptoms caused ...
- DeliveryTime: Within 3 workdays after payment
- PackAge: 1kg/BAG,25kg/DRUM,according to custom...
- Port: China main port
- ProductionCapacity: 10000 Metric Ton/Month
- Purity: 99%
- Storage: -20°C Freezer, Under Inert Atmosphere
- Transportation: Air, sea, land transport
- LimitNum: 1 Kilogram
- Related Substances: 0
- Residue on Ignition: <0.5
- Heavy Metal: <0.003%
- Valid Period: 2 years
Superiority
Details
the CysLT2 receptor. In rat colitis Montelukast Sodium has demonstrated the ability to increase PGE2 (Prostaglandin E2 -
sc-201225) production and lower COX-2 expression. Inhibition is competitive with respect to leukotrienes - particularly LTD4, a
biologically active mediator that plays an important role in the control of several biochemical pathways involving pulmonary and
immune system function.Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again
because of its very specific mechanism of action, it does not interact with other asthma medications such as theophylline.Another
leukotriene receptor antagonist is zafirlukast (Accolate), taken twice daily. Zileuton (Zyflo), an asthma drug taken four times
per day, blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway.
seasonal allergies.Montelukast comes as a tablet, a chewable tablet, flash tablet and granules to take by mouth.Montelukast is
usually taken once a day with or without food.Montelukast is a CysLT1 antagonist; it blocks the action of leukotriene D4 (and
secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it.
This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation.
dysmenorrhoea and urticaria. It is mainly used as a complementary therapy in adults in addition to inhaled corticosteroids, if
they alone do not bring the desired effect. It is also used to prevent allergic reactions and asthma flare-ups during the
administration of intravenous immunoglobulin.